Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia 26Lymphoma, Large B-Cell, Diffuse 22Breast Neoplasms 21Lymphoma, Follicular 18Leukemia, Myeloid, Acute 18Burkitt Lymphoma 16Multiple Myeloma 15Lymphoma, Non-Hodgkin 15Lymphoma, Mantle-Cell 14Leukemia, Lymphocytic, Chronic, B-Cell 13Hodgkin Disease 13Lymphoma, Large-Cell, Immunoblastic 12Neuroblastoma 11Melanoma 11Myelodysplastic Syndromes 10Lymphoma, B-Cell, Marginal Zone 10Neoplasms, Plasma Cell 9Sarcoma 8Leukemia, Myeloid, Chronic-Phase 8Neutropenia 7Central Nervous System Neoplasms 7Myeloproliferative Disorders 6Medulloblastoma 6Leukemia, Myelomonocytic, Acute 6Congenital Abnormalities 6Waldenstrom Macroglobulinemia 5Neoplasms 5Leukemia, Myelomonocytic, Chronic 5

Interventions

Carboplatin 17Paclitaxel 16Radiotherapy 10Taxes 9Cisplatin 8Radiation 7Docetaxel 7Gemcitabine 6Gefitinib 6Bevacizumab 6Erlotinib Hydrochloride 5Radiotherapy, Conformal 3Platinum 3Etoposide 31,2-diaminocyclohexaneplatinum II citrate 3methoxyamine 2Vinorelbine 2Tirapazamine 2Pemetrexed 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cetuximab 2Bortezomib 2veliparib 1vandetanib 1shark cartilage extract 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma of Lung × Filgrastim × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡